EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BioVersys AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioVersys Announces First Subjects Dosed in Ph 1 Clinical Trial of BV100","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Curetis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AMR Action Fund Announces Investment in BioVersys AG","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$49.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of its Series C Round by CHF 12.3 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"CF AMR Syndicate","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by BioVersys AG

    Menu

    BioVersys AG

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              BioVersys AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme

              Details:

              The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).

              Lead Product(s): BV500

              Therapeutic Area: Infections and Infectious Diseases Product Name: BV500

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: CF AMR Syndicate

              Deal Size: $0.6 million Upfront Cash: Undisclosed

              Deal Type: Funding June 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioVersys AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

              Details:

              The proceeds will enable the clinical development of BioVersys’ portfolio which includes BV100 (rifabutin), a potential breakthrough hospital antibiotic with a new mode of action targeting Acinetobacter baumannii, the most drug-resistant bacterial pathogen.

              Lead Product(s): Rifabutin

              Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: GSK

              Deal Size: $49.5 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing May 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioVersys AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of its Series C Round by CHF 12.3 Million

              Details:

              The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.

              Lead Product(s): Alpibectir,Ethionamide

              Therapeutic Area: Infections and Infectious Diseases Product Name: BVL-GSK098

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: GSK

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioVersys AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AMR Action Fund Announces Investment in BioVersys AG

              Details:

              BioVersys' lead candidate, BV100 (rifabutin), is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).

              Lead Product(s): Rifabutin

              Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: AMR Action Fund

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing January 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioVersys AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

              Details:

              BV100 is a much-needed injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii in patients with ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia and bloodstream infections.

              Lead Product(s): Rifabutin

              Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Curetis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioVersys AG

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioVersys Announces First Subjects Dosed in Ph 1 Clinical Trial of BV100

              Details:

              BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.

              Lead Product(s): Rifabutin

              Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY